Sanofi Earnings Call: Profitable Growth Amid Rising Risks

Sanofi SA ((SNY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Sanofi’s Earnings Call Balances Strong Growth With Manageable Risks

Sanofi’s latest earnings call painted a broadly upbeat picture of a company delivering solid growth, strengthening profitability and actively refreshing its pipeline, even as it acknowledges some notable clinical setbacks, safety questions and regulatory uncertainties. Robust top-line momentum, record contributions from new launches, expanding margins and a strong balance sheet underpinned a positive tone. Management emphasized that these positives more than offset challenges such as a failed Phase III trial for tolebrutinib, a safety signal in amlitelimab, reduced R&D reimbursements from Regeneron and some clouds on the U.S. vaccine horizon.

Double-Digit Growth Caps a Strong Year

Sanofi reported a strong top-line performance for 2025, with net sales reaching €43.6 billion, up 9.9% at constant exchange rates, and fourth-quarter revenue of €11.3 billion, a 13.3% year-on-year increase. This acceleration into year-end highlights both the resilience of the existing portfolio and the traction of newer products. For investors, the combination of nearly double-digit annual growth and an even stronger Q4 suggests that Sanofi enters 2026 with good momentum across key franchises rather than relying on a single product or one-off tailwind.

New Launches Deliver Scale and Diversification

Launch performance was a central theme, with new products generating €5.7 billion in 2025 sales, up 34%. Several assets reached or approached critical mass: hemophilia therapy ALTUVIIIO achieved blockbuster status with €1.2 billion in annual sales, AYVAKIT posted $725 million in pro forma sales, and Beyfortus contributed €1.8 billion, growing 9.5%. Management framed these launches as proof that Sanofi’s innovation engine is translating into meaningful revenue, diversifying beyond legacy franchises and supporting the company’s medium-term growth aspirations.

Dupixent Continues to Power the Growth Story

Dupixent remains Sanofi’s flagship growth driver, with €4.2 billion in Q4 sales and €15.7 billion for the full year, supported by more than 30% growth in patient numbers over the past 12 months. The company highlighted multiple new indications as key levers for future expansion, including chronic obstructive pulmonary disease (COPD), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP), alongside a new regulatory acceptance in allergic fungal rhinosinusitis (AFRS). This expanding label and disease footprint reinforces Dupixent’s role as a multi-billion-euro cornerstone asset with substantial runway.

Vaccines Remain a Strategic Pillar Despite Near-Term Noise

Sanofi underscored its leadership in vaccines, which generated €7.9 billion in sales in 2025. Beyfortus, designed to protect infants against RSV, has already been used to protect more than 11 million babies in over 45 countries and has demonstrated real-world effectiveness of 87%–98%, with an estimated ~200,000 hospitalizations prevented. While vaccine revenues remain a key contributor and a reputation builder, management also flagged uncertainties related to changes in U.S. pediatric immunization recommendations that could impact Beyfortus exposure and overall vaccine uptake in 2026.

Margins and Earnings Move Up the Quality Curve

Profitability improved meaningfully in 2025. Business gross margin expanded by 1.8 percentage points to 77.5%, and business operating income rose 11.9%, delivering a BOI margin of 27.8%. Business EPS growth was strong, with Q4 business EPS up 26.7%, and full-year business EPS increasing 12.2% excluding buybacks and 15% including the completed €5 billion share repurchase. Management presented this as evidence that Sanofi can grow profitably—leveraging scale, mix and cost discipline—rather than relying solely on revenue growth to drive shareholder value.

Cash Generation and Balance Sheet Support Strategic Flexibility

Sanofi generated €8.1 billion of free cash flow in 2025, representing 18.5% of sales, while also reducing inventory by nearly 30 days. Net debt stands at around €11 billion, translating into a conservative net debt-to-EBITDA ratio of 0.8x and supporting an AA credit rating. This financial strength underpins capital returns and deal-making: the board is proposing a €1 billion buyback in 2026 and a 5% dividend increase to €4.12 per share. Investors are being told to expect both continued reinvestment in innovation and sustained cash returns.

Pipeline Execution and Regulatory Wins Build Future Optionality

Management highlighted a high level of pipeline activity in 2025: 12 Phase III readouts, 15 Phase II readouts, 10 new Phase I molecules (including three gene therapies), 20 regulatory approvals and 22 regulatory acceptances—nine of which were priority reviews. Sanofi also launched three new medicines and vaccines—Qfitlia, Wayrilz and Nuvaxovid—during the year. This breadth of late-stage and regulatory progress is intended to reassure investors that the company can replenish and grow its portfolio as some older assets mature.

Active Business Development and M&A as Growth Accelerators

Sanofi has been aggressive in deploying the roughly €10.4 billion in proceeds from the Opella divestment into business development and M&A. Key deals include transactions with Blueprint, Vicebio, Dren Bio (DR-0201), Vigil and the proposed acquisition of Dynavax, which would add HEPLISAV-B and a shingles vaccine candidate to the portfolio. Management portrayed this deal-making as targeted and value-oriented, designed to strengthen core therapeutic areas and vaccines rather than diversify indiscriminately.

Operational Investments and Sustainability Agenda

Beyond financial metrics, Sanofi emphasized its ongoing investment in manufacturing capacity, with a particular focus on the U.S. These projects are meant to support growing patient demand and meet contractual commitments, even if they increase near-term capital expenditure and operational complexity. The company also highlighted its role in developing PAS 2090, the first industry-wide global standard for measuring and reducing the environmental impact of medicines and vaccines, signaling that sustainability and operational efficiency are being integrated into long-term planning.

Clinical Setback: Tolebrutinib Misses in Progressive MS

Not all pipeline news was positive. Tolebrutinib failed to meet the primary endpoint in the Phase III PERSEUS study in primary progressive multiple sclerosis (PPMS), prompting Sanofi to abandon regulatory plans for that indication. While the company may still explore tolebrutinib in other MS segments, this result removes a potential growth option and illustrates the inherent risk in late-stage neurology programs. The setback underscores the need for Sanofi’s broader portfolio strategy to deliver replacement opportunities.

Changing Economics: Regeneron Reimbursement Declines

Sanofi flagged a material shift in its P&L from 2026 onward as R&D reimbursement from Regeneron decreases by about €400 million, larger than previously expected. While the impact is partly offset by higher Amvuttra royalties—around €1 billion expected in 2026—the company anticipates a net negative impact on business operating income of roughly €400 million in 2027. Management’s message is that portfolio and pipeline performance should absorb this drag over time, but investors are being prepared for a transitional period in earnings composition.

Vaccine Market Uncertainty and 2026 Revenue Headwind

The company acknowledged that recent changes to U.S. pediatric immunization recommendations could cause confusion among parents and healthcare providers, introducing uncertainty for vaccines on the schedule, including Beyfortus. Management plans to monitor the situation through 2026 and provide more visibility as the year progresses. Against this backdrop, Sanofi expects a slight decline in vaccine sales in 2026, further impacted by about €200 million of sales reduction from continued portfolio optimization and divestments.

Monitoring Amlitelimab’s Safety Profile

Sanofi disclosed a Kaposi sarcoma case associated with human herpesvirus (HHV) in the amlitelimab program. While the company reports no additional similar cases and maintains that the overall benefit-risk profile remains intact, it acknowledged that this may reveal a mechanistic sensitivity to herpes viruses. As amlitelimab progresses, regulators and investors will be watching safety data closely, given the high bar for novel immunology agents and the commercial importance of maintaining a clean safety profile.

Higher Financial Costs and Pipeline Rationalization

The company expects financial expenses to rise in 2026 as net debt increases due to stepped-up M&A activity. At the same time, Sanofi has been pruning its pipeline, rationalizing parts of the Phase II portfolio to sharpen capital allocation. Some assets, such as itepekimab, still require additional regulatory dialogue to define Phase III pathways, injecting timing and execution uncertainty. Management framed these decisions as disciplined portfolio management, prioritizing programs with the clearest clinical and commercial potential.

Scaling Manufacturing to Match Demand

Sanofi plans continued investment in manufacturing capacity, especially in the U.S., to support growing demand and fulfill commitments under minimum financial needs agreements. While this will increase near-term CapEx and operational focus, it is presented as a necessary step to secure supply for key products and future launches. For investors, this signals that the company is willing to front-load infrastructure spending today to underpin tomorrow’s revenue and margin opportunities.

Forward Guidance Anchored in Profitable Growth

For 2026, Sanofi guided to “high single-digit” sales growth, with business EPS expected to grow slightly faster than revenue—indicating continued margin improvement despite some headwinds. Management expects vaccine sales to decline slightly and around €200 million of sales to be lost from portfolio divestments. Nonetheless, they see further gross-margin expansion, about €500 million of capital gains within operating income, and a moderate increase in underlying R&D spend. The roughly €400 million reduction in Regeneron R&D reimbursement should be more than offset by around €1 billion in Amvuttra royalties, though higher financial expenses are anticipated due to increased net debt. A €1 billion share buyback is planned for 2026. This guidance is built on a strong 2025 base of €43.6 billion in sales, a 27.8% BOI margin, and €8.1 billion of free cash flow (18.5% of sales), with a medium-term ambition to reach at least 20% FCF and maintain balance-sheet capacity for ongoing M&A.

In closing, Sanofi’s earnings call framed a company in solid health: double-digit growth, rising margins, strong cash generation and an increasingly diversified portfolio led by Dupixent and a suite of high-growth launches. While investors must weigh clinical setbacks, safety monitoring in key programs and uncertainty in the U.S. vaccine market, management’s guidance points to continued profitable growth and active capital deployment. For shareholders and prospective investors, the story remains one of steady execution with manageable, clearly articulated risks.